Formosa Biomedical Signs Strategic Partnership with Rohto Pharmaceutical to Expand Regenerative Medicine in Taiwan and Japan

Formosa Biomedical Technology Corp.

Formosa Biomedical Technology Corp., representing the Formosa Plastics Group’s regenerative medicine division (including Ivy Life Sciences), signed a strategic partnership agreement with the globally renowned Rohto Pharmaceutical Co., Ltd. on July 22. This collaboration marks the first time a Taiwanese company has been entrusted by a Japanese pharmaceutical firm with regenerative medicine CDMO (Contract Development and Manufacturing Organization) services. The agreement will also facilitate the entry of Formosa Biomedical’s regenerative medicine products into the Japanese market, enabling bi-directional technology integration and product deployment, thereby expanding the regenerative medicine ecosystem in both Taiwan and Japan.

Chairperson Sandy Wang of Formosa Biomedical stated that regenerative medicine is a key driver of future medical innovation, offering new treatment opportunities through the activation and repair of human tissues and cells. The Formosa Plastics Group has long been dedicated to integrating industrial and medical resources to create new possibilities for the regenerative medicine industry. She expressed her deep honor in establishing this strategic partnership with Rohto Pharmaceutical, internationally recognized for its eye-care products and Mentholatum dermatological treatments, and for its strong technological foundation in regenerative medicine. Moving forward, the collaboration will leverage Formosa Biomedical’s strengths in R&D, clinical trials, and manufacturing capabilities, together with Rohto’s expertise, to expand the Taiwan–Japan regenerative medicine market and bring hope and advanced medical solutions to patients around the world.

General Manager Hui-Chi Liu of Formosa Biomedical added that Formosa Plastics Group currently operates a GTP (Good Tissue Practice) facility in Taoyuan under Ivy Life Sciences, and plans to launch its first GMP-certified regenerative medicine manufacturing facility with full-scale production capacity by 2026. Rohto Pharmaceutical, on the other hand, has already established four regenerative medicine facilities in Japan, amassing extensive experience and a proven track record. Through collaboration in CDMO services, clinical trials, and regulatory approval processes, both parties aim to accelerate market access in Taiwan and Japan while strengthening the global deployment and practical applications of regenerative medicine.

Under its comprehensive corporate vision, “Connect for Well-being”, Rohto Pharmaceutical has been actively developing regenerative medicine solutions to provide new treatment options for patients lacking effective therapies. With the mission of “making regenerative medicine more accessible and user-friendly”, this partnership will extend Rohto’s regenerative medicine product development and CDMO services beyond Japan and into the Taiwanese market.

Formosa Biomedical continues to demonstrate its strong commitment to preventive medicine, with business operations spanning six major sectors: lifestyle, biotechnology, biochemistry, healthcare, pharmaceuticals, and medical devices. The company has built a robust and diverse biotech ecosystem across Taiwan. In recent years, it has been proactively integrating resources and deepening its investment in regenerative medicine development aiming to reshape the future of healthcare through innovation, enhance public health and well-being, and benefit a broader population.